Alumis
Shereen McIntyre has extensive experience in data management and clinical programming. Shereen is currently serving as the Vice President of Data Management & Clinical Programming at Alumis since June 2023. Prior to that, they held the position of Executive Director of Data Management at Alumis from November 2021 to May 2023. Before joining Alumis, Shereen worked as the Executive Director of Clinical Data Management at Bristol Myers Squibb from November 2020 to August 2021. Shereen also held executive roles in Clinical Data Management at MyoKardia and Five Prime Therapeutics, Inc. from 2016 to 2020. Shereen began their career at Amylin Pharmaceuticals as the Associate Director of Data Management and served in this role for 15 years from 1999 to 2014.
Shereen McIntyre attended UC San Diego from 1996 to 2000, where they obtained a Bachelor's degree in Biochemistry and Cell Biology. Shereen later pursued an MBA in General Management from San Diego State University from 2003 to 2006.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.